Posted by Michael Wonder on 09 Jul 2020
Osmotica Pharmaceuticals receives FDA approval for Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1% for acquired blepharoptosis (droopy eyelid) in adults
9 July 2020 - First and only FDA approved pharmacologic treatment for acquired blepharoptosis.
Osmotica Pharmaceuticals announced today that the U.S. FDA has approved Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1%, formerly known as RVL-1201, its novel treatment for acquired blepharoptosis, or ptosis, a condition characterised by the abnormal drooping of the upper eyelid that can limit field of vision.
Osmotica plans to make Upneeq commercially available next month to a selected group of ophthalmologists and optometrists through an early experience program.
